Yuta Ibe, Tomoyuki Ishigo, Satoshi Fujii, Masahide Fukudo
{"title":"万古霉素血药浓度-时间曲线下初始累积面积与急性肾损伤发生率相关。","authors":"Yuta Ibe, Tomoyuki Ishigo, Satoshi Fujii, Masahide Fukudo","doi":"10.1080/1120009X.2025.2561968","DOIUrl":null,"url":null,"abstract":"<p><p>We aimed to evaluate the relationship between the cumulative area under the concentration-time curve (AUC) for the first and second day of vancomycin (VCM) administration and acute kidney injury (AKI). The primary outcome was the cumulative incidence of AKI. Patients were divided into three groups based on the measured AUC<sub>0-48 h</sub> at the first therapeutic drug monitoring (TDM) (800 to less than 1000 µg·h/mL, Low-AUC group; 1000 to less than 1200 µg·h/mL, Moderate-AUC group; ≥1200 µg·h/mL, High-AUC group). Among 180 enrolled patients, 29 (16.1%) developed AKI. In the multivariate Cox proportional hazard analysis, the Moderate- (hazard ratio [HR]: 5.7, 95% confidence interval [CI]: 2.24-14.44) and High- (HR: 11.0, 95% CI: 3.88-31.39) AUC groups were associated with a higher incidence of AKI compared to the Low-AUC group. The accumulation toxicity of VCM was observed, and the cumulative AUC<sub>0-48 h</sub> was associated with the development of AKI.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Initial cumulative area under the blood concentration-time curve of vancomycin is associated with the incidence of acute kidney injury.\",\"authors\":\"Yuta Ibe, Tomoyuki Ishigo, Satoshi Fujii, Masahide Fukudo\",\"doi\":\"10.1080/1120009X.2025.2561968\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We aimed to evaluate the relationship between the cumulative area under the concentration-time curve (AUC) for the first and second day of vancomycin (VCM) administration and acute kidney injury (AKI). The primary outcome was the cumulative incidence of AKI. Patients were divided into three groups based on the measured AUC<sub>0-48 h</sub> at the first therapeutic drug monitoring (TDM) (800 to less than 1000 µg·h/mL, Low-AUC group; 1000 to less than 1200 µg·h/mL, Moderate-AUC group; ≥1200 µg·h/mL, High-AUC group). Among 180 enrolled patients, 29 (16.1%) developed AKI. In the multivariate Cox proportional hazard analysis, the Moderate- (hazard ratio [HR]: 5.7, 95% confidence interval [CI]: 2.24-14.44) and High- (HR: 11.0, 95% CI: 3.88-31.39) AUC groups were associated with a higher incidence of AKI compared to the Low-AUC group. The accumulation toxicity of VCM was observed, and the cumulative AUC<sub>0-48 h</sub> was associated with the development of AKI.</p>\",\"PeriodicalId\":15338,\"journal\":{\"name\":\"Journal of Chemotherapy\",\"volume\":\" \",\"pages\":\"1-11\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Chemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1120009X.2025.2561968\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2025.2561968","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Initial cumulative area under the blood concentration-time curve of vancomycin is associated with the incidence of acute kidney injury.
We aimed to evaluate the relationship between the cumulative area under the concentration-time curve (AUC) for the first and second day of vancomycin (VCM) administration and acute kidney injury (AKI). The primary outcome was the cumulative incidence of AKI. Patients were divided into three groups based on the measured AUC0-48 h at the first therapeutic drug monitoring (TDM) (800 to less than 1000 µg·h/mL, Low-AUC group; 1000 to less than 1200 µg·h/mL, Moderate-AUC group; ≥1200 µg·h/mL, High-AUC group). Among 180 enrolled patients, 29 (16.1%) developed AKI. In the multivariate Cox proportional hazard analysis, the Moderate- (hazard ratio [HR]: 5.7, 95% confidence interval [CI]: 2.24-14.44) and High- (HR: 11.0, 95% CI: 3.88-31.39) AUC groups were associated with a higher incidence of AKI compared to the Low-AUC group. The accumulation toxicity of VCM was observed, and the cumulative AUC0-48 h was associated with the development of AKI.
期刊介绍：
The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy.
The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs.
Specific areas of focus include, but are not limited to:
· Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents;
· Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy;
· Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents;
· The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs;
· Drug interactions in single or combined applications;
· Drug resistance to antimicrobial and anticancer drugs;
· Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research;
· Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs;
· Pharmacogenetics and pharmacogenomics;
· Precision medicine in infectious disease therapy and in cancer therapy;
· Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
